logo-with-company-name.svg

Capabilities

Our Expertise

Services

Target discovery

Drug Classes

Cooperation

Testimonials

Lead Selection

Lead Optimisation & Characterisation

Our Service Models

Strategic partnerships

Our Equipment

Product Characterisation

Our Team

Biosimilar Characterisation

Careers

News

Contact Us

Tim_London_author_100x100px.jpg

Announcing IndEx-2 In Vitro Cell Based Platform 

<p><span lang="EN-US" dir="ltr">Antibody Analytics is proud to announce the product launch of our highly anticipated </span><a target="_blank" rel="noopener noreferrer" href="https://cld.antibodyanalytics.com/index-2"><span lang="EN-US" dir="ltr">IndEx-2</span></a><span lang="EN-US" dir="ltr"> platform!</span></p><p>The number of antibody-targeted I-O therapeutics in development is growing year after year. However, there persists a lack of <i>in vitro</i> systems to interrogate the efficacy and safety of these modalities.&nbsp;&nbsp;</p><p>In response to this, we have developed <a target="_blank" rel="noopener noreferrer" href="https://cld.antibodyanalytics.com/index-2">IndEx-2</a>, an advanced <i><strong>in vitro</strong></i><strong> cell-based platform</strong> which allows the expression of one, or two, target antigens over a range of <strong>biologically relevant levels</strong>, allowing the determination of the precise antigen density activation thresholds of targeted candidate immunotherapies and antibody-based therapeutics.</p><p><a target="_blank" rel="noopener noreferrer" href="https://cld.antibodyanalytics.com/index-2"><span lang="EN-US" dir="ltr">IndEx-2</span></a><span lang="EN-US" dir="ltr"> unlocks massive potential across the biotechnology sector, and the wider biopharmaceutical field. With this being our first official product launch, we are looking forward to pushing the boundaries of drug discovery and data collection through our bespoke new </span><a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/best-practices-in-cell-line-development"><span lang="EN-US" dir="ltr">cell line development</span></a><span lang="EN-US" dir="ltr"> platform.</span></p><div class="raw-html-embed"><div class="center"><a href="https://cld.antibodyanalytics.com/index-2" target="_blank" class="external-btn-primary">Discover more on IndEx-2</a></div></div><h2><span lang="EN-US" dir="ltr"><strong>Customization</strong></span></h2><ul style="list-style-type:disc;"><li><span lang="EN-US" dir="ltr">The platform can be rapidly customized, to provide inducible expression of any target antigen of interest (TAOI) in the same genetic background.</span></li><li><span lang="EN-US" dir="ltr">Orthogonal titration systems allow for the finely controlled expression of one to two TAOIs, over an extensive dynamic range.</span></li></ul><h2><span lang="EN-US" dir="ltr"><strong>Therapeutic window determination</strong></span></h2><p><span lang="EN-US" dir="ltr">Fine control of TAOI expression with </span><a target="_blank" rel="noopener noreferrer" href="https://cld.antibodyanalytics.com/index-2"><span lang="EN-US" dir="ltr">IndEx-2</span></a><span lang="EN-US" dir="ltr"> allows healthy and disease state levels to be modelled on the backdrop of the same genetic background, this enables.</span></p><ul><li><span lang="EN-US" dir="ltr">The determination of the <strong>minimum activation threshold</strong> – know when and how your molecule will be activated.</span></li><li><i><span lang="EN-US" dir="ltr">in vitro&nbsp;</span></i><span lang="EN-US" dir="ltr">modelling to assess the likelihood of “on target, off tumor” toxicities</span></li></ul><h2><span lang="EN-US" dir="ltr"><strong>High content data generation</strong></span></h2><p><a target="_blank" rel="noopener noreferrer" href="https://cld.antibodyanalytics.com/index-2"><span lang="EN-US" dir="ltr">IndEx-2</span></a><span lang="EN-US" dir="ltr"> is a model system that is compatible with our extensive range of </span><i><span lang="EN-US" dir="ltr">in vitro&nbsp;</span></i><span lang="EN-US" dir="ltr">bioassays and primary immune cell assays, like our unique </span><a target="_blank" rel="noopener noreferrer" href="https://immunology.antibodyanalytics.com/t-cell-exhaustion"><span lang="EN-US" dir="ltr">exhausted human T cell model</span></a><span lang="EN-US" dir="ltr"> amongst many other options.</span></p><p><a target="_blank" rel="noopener noreferrer" href="https://cld.antibodyanalytics.com/index-2"><span lang="EN-US" dir="ltr">IndEx-2</span></a><span lang="EN-US" dir="ltr"> is compatible with:</span></p><ul style="list-style-type:disc;"><li><span lang="EN-US" dir="ltr">T cell activation and cytotoxicity assays; T cell engagers and CAR-T cell therapies</span></li><li><span lang="EN-US" dir="ltr">NK cell activation and cytotoxicity assays; NK cell engagers and CAR-NK cell therapies</span></li><li><a target="_blank" rel="noopener noreferrer" href="https://share.hsforms.com/1WkCrgyUVTnSdqse0XFl7jw4v8st"><span lang="EN-US" dir="ltr">Cytotoxicity assays</span></a><span lang="EN-US" dir="ltr">; for ADCs</span></li><li><span lang="EN-US" dir="ltr">Effector function assays; for monoclonal antibodies</span></li></ul><h2><span lang="EN-US" dir="ltr"><strong>Seamless integration – Compatible with Antibody Analytics’ functional immunology assays&nbsp;</strong></span></h2><p>Would you like to find out more about how Antibody Analytics can assist you with your drug discovery journey? Get in touch with our team so we can collaborate and create beautiful datasets.&nbsp;</p><p>We are committed to your drug discovery journey.&nbsp;</p><div class="raw-html-embed"><div class="center"><a href="https://share.hsforms.com/1NI8r5BK2SU-URRbXleyCBA4v8st" target="_blank" class="external-btn-primary">Speak to a molecular biologist</a></div></div>

IndEx2 Introducing IndEx2 Discover the New Solution for Measuring the Safety and Efficacy of Your Therapeutic -02.png

IndEx2 Introducing IndEx2 Discover the New Solution for Measuring the Safety and Efficacy of Your Therapeutic -01.png

Our latest new development is the launch of our transformative inducible cell line development platform: IndEx-2. 

Introducing IndEx-2: The New Solution for Measuring the Safety & Efficacy of Your Therapeutic

Michahaila_Downie_author_100x100px.jpg

Celebrating One Year of the Antibody Analytics Discovery Centre with Discovery Week

<p style="margin-left:0px;">Can you believe it's been a whole year since we opened the doors to the Antibody Analytics Discovery Centre? We can't either! It feels like just yesterday that we were setting up our lab equipment and getting ready to take on this exciting new challenge. The 29th of May – 2nd of June marks ‘Discovery Week’ here at Antibody Analytics. A chance for us to celebrate as a team and promote discovery throughout the wider industry. Since cutting the ribbon on the Discovery Centre in May 2022, we've achieved some amazing milestones, and we're excited to share them with you.</p><h2 style="margin-left:0px;"><strong>From a seed to a forest: A year of exponential growth</strong></h2><p style="margin-left:0px;">Since opening our Discovery Centre, we've been able to expand our team and provide our clients with even better service. It's been amazing to watch our team grow by leaps and bounds.</p><p style="margin-left:0px;">With more hands on deck, 81 to be exact, we're able to take on more projects and deliver these more efficiently. Our clients have come to rely on us for high-quality service and quick turnaround times, and we're pleased to deliver on those expectations.</p><p style="margin-left:0px;">We're not stopping there! We're continuing to <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/careers">recruit throughout 2023 </a>as we look to expand our team even further. We're always on the lookout for talented individuals who are passionate about developing antibody-based therapies and making a real difference in the world.</p><p><img src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/1_f6b43cb519.png" alt="1.png" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_1_f6b43cb519.png 245w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_1_f6b43cb519.png 500w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_1_f6b43cb519.png 750w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/large_1_f6b43cb519.png 1000w," sizes="100vw"></p><h2 style="margin-left:0px;"><strong>Revolutionising the study of antibody-targeted therapies:&nbsp;Say Hello to IndEx-2</strong></h2><p style="margin-left:0px;">We're particularly proud to have launched our <i>in vitro</i> cell-based platform,<a target="_blank" rel="noopener noreferrer" href="https://cld.antibodyanalytics.com/index-2"> <strong>IndEx-2</strong>,</a> which allows for the determination of the precise antigen density activation thresholds of targeted candidate immunotherapies. That's a mouthful, we know, but it's a game-changer!</p><p style="margin-left:0px;">When combined with our immuno-oncology primary cell assay services, IndEx-2 can help pre-clinical researchers better understand a targeted drug candidate's mechanism of action and safety profile. This is invaluable in the development of antibody-targeted therapies such as CAR-engineered cell therapies, bispecifics, multispecifics, immune cell engagers, monoclonal antibodies and ADCs.</p><p style="margin-left:0px;">With IndEx-2, we can provide our clients with even more detailed information about their drug candidates, allowing them to make more informed decisions and accelerate the drug development process. We believe that IndEx-2 is a game-changer for antibody-based therapy development, and we're proud to be leading the change. We can't wait to support the development of the next wave of incredible therapies that will progress to clinic faster as a result of this revolutionary platform.</p><p><img src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/3_720eea6fdc.png" alt="3.png" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_3_720eea6fdc.png 245w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_3_720eea6fdc.png 500w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_3_720eea6fdc.png 750w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/large_3_720eea6fdc.png 1000w," sizes="100vw"></p><h2 style="margin-left:0px;"><strong>Proudly Making Waves: An Award-Winning Year</strong></h2><p style="margin-left:0px;">Antibody Analytics is not only taking the world of antibody-based therapies by storm, but we're also making waves in the life sciences industry. We're excited to announce that since the opening of our Discovery Centre in Motherwell, we've been honoured with some pretty impressive awards.</p><p style="margin-left:0px;">We've been awarded a Gold Award in the North Lanarkshire Employee Charter for creating a positive and supportive work environment. We're also proud to have been named Life Science Company of the Year at the Made in Scotland Awards. This award recognises the most innovative and dynamic companies from across Scotland, and we're honoured to be counted among them. And last but not least, we took home the Innovation: Pharma Services and Drug Discovery Award at Scotland's Life Sciences Annual Awards. This award acknowledges our cutting-edge research and development efforts.</p><p style="margin-left:0px;">We're humbled and grateful for the recognition we've received and look forward to continuing to push the boundaries of what's possible in the field.</p><p style="margin-left:0px;">It's been an incredible 12 months since opening the Antibody Analytics Discovery Centre. We've grown, we've launched new services, and we've helped our clients take potentially life-saving therapies closer to the patients who need them. But we couldn't have done it without our amazing team and the support of our clients and partners.</p><p style="margin-left:0px;">We're looking forward to another year of growth and innovation, and we hope you'll join us for the journey. Here's to Discovery Week, and to many more years of success!</p><p><img src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/2_e934d42ecb.png" alt="2.png" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_2_e934d42ecb.png 245w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_2_e934d42ecb.png 500w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_2_e934d42ecb.png 750w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/large_2_e934d42ecb.png 1000w," sizes="100vw"></p>

Blog header image 2.png

Discovery Week Blog Image_1.png

The 29th of May – 2nd of June marks ‘Discovery Week’ here at Antibody Analytics. A chance for us to celebrate as a team and promote discovery throughout the wider industry. Since cutting the ribbon on the Discovery Centre in May 2022, we've achieved some amazing milestones, and we're excited to share them with you.

Robert Benson.jpg

Treg function, Treg suppression and your therapeutic candidate

<p>Our Treg suppression assay formats are adaptable, using natural Tregs isolated from PBMCs, or induced Tregs expanded and differentiated from naïve CD4+ T cells. Routinely, autologous PBMCs are used as the population to be suppressed, however, the system is open to modification to use pan-T cells, CD4+ or CD8+ T cells as required. Our expert immunologists work closely with you to design the most appropriate system to achieve your goals.</p><div class="raw-html-embed"><div class="center"><a href="https://meetings.hubspot.com/stefan-donevski/website" target="_blank" class="external-btn-primary">Contact our team to discuss your project</a></div></div><p><br><strong>What are regulatory T Cells?</strong></p><p>Tregs have the ability to suppress the function of other lymphocytes by releasing immunosuppressive cytokines such as IL-10 and TGFβ. These cytokines also act to promote polarisation of CD4+ T cells in the periphery to create more Tregs, acting as a positive feedback loop. Tregs can inhibit the activities of CD4+ and CD8+ effector T cells, Natural Killer (NK) cells, NKT cells and antigen presenting cells (APCs) through multiple mechanisms.</p><p>Tregs are defined by functional and phenotypic markers, most notably the expression of the transcription factor FoxP3 and high expression of CD25.</p><p>An imbalance in the number of Tregs is associated with various disease states. Too many Tregs can lead to immunosupression, creating an environment which favours the survival of tumour cells. Conversely, too few Tregs are associated with several autoimmune disorders as the immune system is left unchecked.</p><p>&nbsp;</p><p><img src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/1494085_Treg_Cell_diagram_for_blog_1920x1080_110722_37e804dd12.png" alt="1494085_Treg Cell diagram for blog_1920x1080_110722.png" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_1494085_Treg_Cell_diagram_for_blog_1920x1080_110722_37e804dd12.png 245w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_1494085_Treg_Cell_diagram_for_blog_1920x1080_110722_37e804dd12.png 500w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_1494085_Treg_Cell_diagram_for_blog_1920x1080_110722_37e804dd12.png 750w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/large_1494085_Treg_Cell_diagram_for_blog_1920x1080_110722_37e804dd12.png 1000w," sizes="100vw"></p><p><span style="font-size:13px;"><strong>Figure 1: Tregs mediate suppression by multiple mechanisms regulating inflammatory processes, preventing auto-immunity and also contributing to poor tumour immunity. Tregs can act directly on responding effector T cells via immunosuppressive cytokines e.g. IL-10, IL-35, TGFbeta; metabolic interference e.g. production of adenosine (ADO) from ATP, sequestration of IL-2 and even cytolysis. These mechanisms can also impact antigen presenting cells such as dendritic cells, dampening their activation and ability to effectively stimulate adaptive immune responses.</strong></span></p><p><strong>What is a Treg suppression assay?</strong></p><p>When combined <i>in vitro</i>, Tregs inhibit the proliferation and activation of T cells in response to recognition of specific antigen. Tregs are combined with autologous PBMCs (containing both responder CD4+ and CD8+ T cells as targets for suppression) and a source of T cell stimulation e.g. anti-CD3. Since natural Tregs exist in low numbers, this can limit assay size, however use of expanded iTregs allows larger scale assays to be performed.</p><p>Proliferation and activation of the responder T cells is determined in the presence and absence of Tregs so that the degree of suppression caused by the Tregs can be expressed in terms of inhibition of maximal responses. This can be coupled with cytokine release measurements (ELISA or multiplex cytokine analysis) and phenotyping for activation markers in the regulatory and responder populations to provide high content information to delve deeper into the mechanistic effects of a test therapeutic.&nbsp;</p><p><strong>When to use Treg suppression assays</strong></p><p>A number of therapeutics in development aim to target Treg function in an attempt to alleviate immuno-suppression. One proposed mechanism of action of the approved CTLA-4 targeting antibody, ipilimumab, is that it enhances antitumor immunity by inhibiting the immunosuppressive activity of regulatory T cells. Anti-CTLA4 binding to Tregs can simultaneously mark them for ADCC-mediated destruction.</p><p><strong>Learn more about Antibody Analytics’ Treg suppression models</strong></p><p>In our whitepaper, we describe how scientists from Antibody Analytics have established a Treg suppression assay workflow. The assay covers the isolation of natural Treg cells from peripheral blood mononuclear cells (PBMCs) and co-culture with anti-CD3 stimulated autologous PBMCs at different Treg to PBMC ratios to demonstrate functional suppression of the responder (conventional or Tconv) T cell population. This is coupled with Treg immunophenotyping, cytokine release and Treg-specific reversal of suppressive activity with a novel immunotherapy.</p><div class="raw-html-embed"><div class="center"><a href="https://share.hsforms.com/1Bdt5OpFYSsGLEWtsqkSiWA4v8st" target="_blank" class="external-btn-primary">Access our whitepaper to find out more</a></div></div>

Treg-suppression-hero.png

Treg-suppression-thumbnail.png

Our Treg suppression assay formats are adaptable, using natural Tregs isolated from PBMCs, or induced Tregs expanded and differentiated from naïve CD4+ T cells.

Treg suppression assays for testing immuno-oncology and auto-immunity drugs

<p>Regulatory T cells (thymically and peripherally derived Treg) have critical roles in maintaining immune homeostasis and controlling aberrant/excessive responses to self and non-self antigens. Typically defined as CD4 T cells with high expression of CD25 and FoxP3, these cells mediate tolerance to autoantigens, microflora and food antigens. While there is considerable interest in harnessing Treg activity therapeutically in autoimmune and tissue transplant settings, their activity has garnered significant interest in the immuno-oncology field.</p><h2>Learn more about our Treg Suppression model&nbsp;</h2><p>In our whitepaper, we describe how scientists from Antibody Analytics have established a complete Treg suppression assay workflow. The assay includes isolation of natural Treg cells from peripheral blood mononuclear cells (PBMCs) and co-culture with anti-CD3 stimulated autologous PBMCs at different Treg to PBMC ratios to demonstrate functional suppression of the responder (conventional or Tconv) T cell population. This is coupled with Treg immunophenotyping, cytokine release and Treg-specific reversal of suppressive activity with a novel immunotherapy.&nbsp;</p><div class="raw-html-embed"><div class="center"><a href="https://share.hsforms.com/1Bdt5OpFYSsGLEWtsqkSiWA4v8st" target="_blank" class="external-btn-primary">Access the whitepaper to find out more</a></div></div><p>&nbsp;</p><figure class="image image_resized" style="width:50%;"><img src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/isolated_natural_regulatory_t_cells_36fedf3297.png" alt="isolated_natural_regulatory_t_cells.png" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_isolated_natural_regulatory_t_cells_36fedf3297.png 245w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_isolated_natural_regulatory_t_cells_36fedf3297.png 500w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_isolated_natural_regulatory_t_cells_36fedf3297.png 750w," sizes="100vw"></figure><p>&nbsp;</p><h2>Why Tregs?&nbsp;</h2><p>Tregs are enriched in the tumour microenvironment (TME) and in this context are tumour-permissive, facilitating immune evasion and tumour progression. Tregs are able to suppress conventional CD4 and CD8 T cell responses preventing their efficient targeting of cancer cells, mediating their suppressive function by a variety of mechanisms including: secretion of inhibitory cytokines (e.g. TGFβ, IL-10 and IL-35); suppression by metabolic interference (e.g. by sequestration of IL-2 by means of high CD25 expression or by inhibition via the adenosine pathway); suppression by cytolysis (e.g. granzyme A/B production); and modulation of dendritic cell (DC) function (e.g. via CTLA-4/ CD80/CD86 or LAG3/MHC Class II interactions with DCs) (Figure 1).&nbsp;</p><p>These mechanisms are multi-faceted, temporally and spatially, impacting both priming and effector T cell responses in lymphoid and TME settings respectively, in addition to the conditioning of antigen presenting cells (APCs) and innate immune cells to dampen anti-tumour activity.</p><h2>Tregs as a potential way to fight cancer&nbsp;</h2><p>Preclinical studies demonstrating that disruption of intra-tumoural Treg activity is associated with reduced tumour burden, and approval of ipilimumab (Yervoy, an anti-CTLA-4 antibody) for treatment of metastatic melanoma, set a clear precedent in targeting this cell population. Accordingly, Tregs and their activity have become attractive candidates in developing novel cancer therapies.&nbsp;</p><div class="raw-html-embed"><div class="center"><a href="https://meetings.hubspot.com/stefan-donevski/website" target="_blank" class="external-btn-primary">Speak to one of our specialists</a></div></div><p>Several therapeutic strategies are now underway to identify different ways in which Tregs may be leveraged for treatment of various tumour types. Numerous Treg targets and approaches are under investigation; CTLA-4, CD25, FoxP3, ubiquitin, GITR, CD39, CCR4, CCR8, IL-10 and TGFβ to name but a few. Consequently, now, more than ever, there is a demand for defined, robust, in vitro Treg assays to test candidate immunotherapies for their ability to modulate Treg phenotype and importantly, functional activity.</p>

Treg suppression-hero.png

Treg suppression-card.png

Regulatory T cells (thymically and peripherally derived Treg) have critical roles in maintaining immune homeostasis and controlling aberrant/excessive responses to self and non-self antigens. 

<h2>The <span style="color:#4EB7F2;">Collaborative</span> immunology CRO</h2><p><span style="color:#4EB7F2;">Enriching your team</span></p>

home page carousel_cells_1.png

The Collaborative Immunology CRO

Antibody Analytics

<h2>The <span style="color:#32CDCD;">Creative</span> immunology CRO</h2><p><span style="color:#32CDCD;">Your challenge is our muse</span></p>

home page carousel_creative_2.png

The Creative Immunology CRO

<h2>The <span style="color:#743DE9;">Consultative</span> immunology CRO</h2><p><span style="color:#743DE9;">Sharing our solutions</span></p>

home page carousel_fur ball_3.png

The Consultative Immunology CRO

<p>Antibody Analytics Ltd.&nbsp;</p><p>VAT Number: GB 235 2396 11 | Registered in Scotland</p>

<h1>Our new revolutionary IndEx-2 system has launched</h1><p>A transformational, inducible cell system that allows selection of the safest and most efficacious targeted therapies. IndEx-2 is an <i>in vitro</i> cell-based platform that provides inducible <strong>expression of any target antigen of interest</strong> (TAOI).</p><ul><li><strong>Safety: </strong>Gain information on the potential of “on target, off tumour effects” via precise control of TAOI expression to model physiological and pathological expression levels</li><li><strong>Efficacy: </strong>Determine the antigen density activation threshold of targeted immunotherapies, including immune cell engagers, ADCs and engineered immune cell therapies</li></ul><p>IndEx-2 is an effective tool that can be used to enhance a pre-clinical data package with information that offers a more comprehensive understanding of a targeted drug <strong>mechanism of action</strong> and <strong>functional profile.&nbsp;</strong></p><p>&nbsp;</p><div class="raw-html-embed"><div class="left"><a href="https://cld.antibodyanalytics.com/index-2" target="_blank" class="external-btn-primary">Find out more</a></div></div>

horn.svg

Antibody Analytics - The Collaborative Immunology CRO

<h1>Meet us in person at upcoming events</h1><p>We’re so pleased to announce that in 2023 we’ll be exhibiting and presenting at two prestigious conferences:&nbsp;</p><ul><li><strong>BIO Boston:</strong> 5-8th June&nbsp;</li><li><strong>Immuno-Oncology Summit Europe in London:</strong> 20-22nd June – stand 7</li></ul><p>&nbsp;</p><div class="raw-html-embed"><div class="left"><a href="https://share.hsforms.com/1YIM97zfBTGOnauA5PZapog4v8st" target="_blank" class="external-btn-primary">Find a suitable time to talk</a></div></div>

The Collaborative immunology CRO

Meet us in person at upcoming events

Our new revolutionary IndEx-2 system has launched

News